Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00253474 · ClinicalTrials.gov registry record · Phase 1
PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma
A Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00253474 is a Phase 1 study that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 36 participants.
The verdict
NCT00253474, a Phase 1 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of PEG-interferon alfa-2b in treating young patients with plexiform neurofibroma.
Interventions
- BIOLOGICAL PEG-interferon alfa-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2005-09 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00253474
The ClinicalTrials.gov registry entry for NCT00253474 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PEG-interferon alfa-2a is the first listed.
NCT00253474 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00253474 about?
NCT00253474 is a clinical study titled "PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma". RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of PEG-interferon alfa-2b in treating young patients with plexiform neurofibroma.
What is the current status of trial NCT00253474?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2005-09. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00253474?
The interventions under investigation include: PEG-interferon alfa-2a (BIOLOGICAL).
Who is sponsoring clinical trial NCT00253474?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.